1. Positive outcome of first-line therapy for a SMARCA4-deficient thoracic sarcomatoid tumor
- Author
-
Hiroaki Ozawa, Shigeru Tanaka, Eiichi Maruyama, Shuhei Hayashi, Masaru Kondo, Motoyasu Okuno, and Yoshitaka Isobe
- Subjects
medicine.medical_specialty ,Combination therapy ,business.industry ,Case Report ,Pembrolizumab ,Malignancy ,medicine.disease ,Carboplatin ,chemistry.chemical_compound ,Pemetrexed ,First line therapy ,chemistry ,Surgical oncology ,SMARCA4 ,Medicine ,Radiology ,business ,medicine.drug - Abstract
SMARCA4-deficient thoracic sarcomatoid tumor is a rare malignancy indicating some characteristics of a smoking-related disease. The purpose of this report is to describe a case of aggressive thoracic tumor with loss of immunochemical SMARCA4 expression and detail the results of our treatment regimen. The patient was a 58-year-old male and clinicopathologically diagnosed with a SMARCA4-deficient thoracic sarcomatoid tumor. Pembrolizumab plus carboplatin and pemetrexed resulted in significant response. This combination therapy showed potential for first-line systemic treatment of SMARCA4-deficient thoracic sarcomatoid tumors.
- Published
- 2021
- Full Text
- View/download PDF